Form 4: Zymeworks CMO Sells Shares for Tax Obligations

Zymeworks' EVP & Chief Medical Officer, Jeffrey T.L. Smith, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax withholding obligations.

Summary

• Jeffrey T.L. Smith, EVP & Chief Medical Officer of Zymeworks Inc., reported transactions on January 12, 2026.
• 17,666 shares of Zymeworks common stock were acquired due to the vesting of restricted stock units (RSUs).
• These RSUs were part of a grant made on January 10, 2025, vesting in three equal annual installments, with this being the first anniversary vesting.
• 9,310 shares of common stock were subsequently sold at a weighted average price of $22.6735 per share to cover tax withholding obligations and other applicable fees.
• The sale was a mandatory "sell to cover" and does not represent a discretionary sale by Mr. Smith.
• Following these transactions, Mr. Smith beneficially owns 26,708 shares of common stock and 35,334 restricted stock units.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is routine and expected, reflecting executive compensation. The 'sell to cover' aspect is standard and not indicative of a discretionary negative view on the stock. The vesting itself is a positive for the executive and aligns interests.

Positives

• Vesting of restricted stock units indicates continued employment and alignment of executive interests with shareholders.
• The sale was non-discretionary, solely for tax purposes, suggesting no intent to reduce personal exposure to the company's stock beyond tax requirements.

Negatives

• A portion of shares were sold, reducing the executive's direct common stock holdings, albeit for tax purposes.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports an executive's stock transactions.

Management Comments

• The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Industry Context

This filing is a routine insider transaction report (Form 4) related to executive compensation, specifically the vesting of restricted stock units and a subsequent 'sell to cover' for tax obligations. It does not provide broader industry context or insights into Zymeworks Inc.'s operational performance or strategic position within the biotechnology or pharmaceutical industry.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting, but the 'sell to cover' is a standard practice and not a discretionary sale. The executive's continued RSU holdings align interests.

Next Steps

• Future vesting events for the remaining RSUs granted on January 10, 2025, are expected to occur on subsequent anniversaries.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and a non-discretionary 'sell to cover' transaction for tax purposes. It does not provide new fundamental information about Zymeworks Inc. that would warrant a change in investment thesis. The executive's continued significant holdings of RSUs suggest ongoing alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Zymeworks Inc., ZYME, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Jeffrey T.L. Smith, Sell to Cover, Tax Withholding